Summary
JOIN PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €569,132 and a net result of €41,311. Equity is growing by about 2.9% per year across the filed financial years. Its solvency ranks better than 48% of 6,658 sector peers (NACE 64, financial year 2025). The company has been active since 2012 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Activity
Activities of holding companies
NACE 64210
1 site
Size
≈ €100,000turnover 2025, estimated
- Equity
- €569,132
- Profit
- €41,311
Turnover estimated from the gross margin
Financial health
Financial institution: outside the modelBankruptcy probability: sector outside the model
SignalsneutralLatest accounts filed on timeShow the evidence
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score weighs liquidity, leverage and margins against norms for trading and manufacturing companies. A bank, insurer or financial holding has a fundamentally different balance-sheet structure, so those ratios, and hence the score, carry no meaning here. That is why we show no financial axes either.
Bankruptcy probability, 12 months
This is a financial institution (bank, insurer or financial holding). A bank balance sheet works differently from that of an ordinary trading or manufacturing company. We therefore show no bankruptcy probability rather than a misleading figure.
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
32 days early
2024
31 days early
2023
26 days early
2022
26 days early
2021
1 day early
2020
3 days early
2019
28 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 21 days before the deadline; the sector median (NACE 64) for financial year 2024 is 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 5 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
28-10-2026 today31-12-2026 year end31-07-2027 deadline
- Annual accounts filedfinancial year 2025 · abbreviated…
- Annual accounts filedfinancial year 2024 · abbreviated…
- Annual accounts filedfinancial year 2023 · abbreviated…
Financials · financial year 2025, abbreviated format
Equity
€569,132▲ 7.8%
2024 · €527,821
Net result
€41,311▲ 45.4%
2024 · €28,420
Total assets
€1.2m▲ 4.7%
2024 · €1.1m
Solvency
48.7%▲ 1.4pp
2024 · 47.3%
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 35% above 2024 and is the highest result in the available series.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result€0.02m
2025
Net result€0.04m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€1.2m
2025
Equity€0.6m
2025
Debt€0.6m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital-€0.3m
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)3.5%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency48.7%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio0.53
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 64, Financial service activities, except insurance and pension funding: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€0.01m-€0.01m▼ 4.4%€0.01m▲ 1.2%€0.01m▼ 5.8%€0.01m▼ 6.9%€0.003m▼ 71.9%€0.02m▲ 399%€0.02m▲ 34.7%
Net result€0.01m-€0.01m▲ 0.9%€0.04mwithin the sector's middle half▲ 255%€0.05mwithin the sector's middle half▲ 23.8%€0.05mwithin the sector's middle half▲ 15.0%€0.06mwithin the sector's middle half▲ 6.3%€0.03mwithin the sector's middle half▼ 48.7%€0.04mwithin the sector's middle half▲ 45.4%
Equity€0.6m-€0.6m▼ 0.4%€0.4mwithin the sector's middle half▼ 27.1%€0.4mwithin the sector's middle half▲ 1.9%€0.5mwithin the sector's middle half▲ 10.9%€0.5mwithin the sector's middle half▲ 10.1%€0.5mwithin the sector's middle half▲ 3.9%€0.6mwithin the sector's middle half▲ 7.8%
Total assets€1.1m-€1.1m▲ 0.8%€1.2mwithin the sector's middle half▲ 2.7%€1.0mwithin the sector's middle half▼ 12.3%€1.0mwithin the sector's middle half▲ 1.8%€1.1mwithin the sector's middle half▲ 4.5%€1.1mwithin the sector's middle half▲ 1.7%€1.2mwithin the sector's middle half▲ 4.7%
Debt€0.6m-€0.6m▲ 2.1%€0.8m▲ 31.3%€0.6m▼ 19.9%€0.6m▼ 4.4%€0.6m▲ 0.2%€0.6m▼ 0.1%€0.6m▲ 1.9%
Working capital-€0.3m--€0.3m▼ 0.9%-€0.4mbelow the sector's middle half▼ 52.0%-€0.4mbelow the sector's middle half▲ 2.0%-€0.4mbelow the sector's middle half▲ 10.5%-€0.3mbelow the sector's middle half▲ 12.0%-€0.3mbelow the sector's middle half▲ 5.9%-€0.3mbelow the sector's middle half▲ 12.2%
Solvency49.5%-48.9%▼ 0.6pp34.7%within the sector's middle half▼ 14.2pp40.4%within the sector's middle half▲ 5.7pp44.0%within the sector's middle half▲ 3.6pp46.3%within the sector's middle half▲ 2.3pp47.3%within the sector's middle half▲ 1.0pp48.7%within the sector's middle half▲ 1.4pp
Current ratio0.50-0.50▲ 0.010.42within the sector's middle half▼ 0.080.29below the sector's middle half▼ 0.130.34below the sector's middle half▲ 0.050.42within the sector's middle half▲ 0.080.45within the sector's middle half▲ 0.030.53within the sector's middle half▲ 0.08
Return on assets (ROA)0.9%-0.9%=3.1%within the sector's middle half▲ 2.2pp4.4%within the sector's middle half▲ 1.3pp5.0%within the sector's middle half▲ 0.6pp5.1%within the sector's middle half▲ 0.1pp2.5%within the sector's middle half▼ 2.5pp3.5%within the sector's middle half▲ 1.0pp
above
within
below
the middle half of NACE 64, Financial service activities, except insurance and pension funding: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.2m
Fixed assets
€851,942 ▲ 0.2%
Current assets
€316,443 ▲ 19.0%
Equity and liabilities €1.2m
Equity
€569,132 ▲ 7.8%
Debt
€599,253 ▲ 1.9%
Debt's share of the balance-sheet total falls from 52.7% to 51.3%. Equity and debt are higher.
Key figures and ratios
ROE
7.3%▲
2024 · 5.4%
Debt ≤ 1 year
€598,953▲
2024 · €587,567
Income taxes
€8,452▲
2024 · €6,077
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €255 | €613 | €737 | €815 | €203 | €79 | €0 | €145 | - |
| Other operating charges640/8 | - | - | - | €172 | €807 | €126 | €0 | €998 | - |
| Gross operating margin9900 | €12,915 | €12,717 | €12,981 | €12,516 | €11,749 | €3,226 | €15,075 | €21,456 | ▲ 42.3% |
| Operating profit (loss)9901 | €12,660 | €12,105 | €12,245 | €11,529 | €10,739 | €3,021 | €15,075 | €20,313 | ▲ 34.7% |
| Financial income75/76B | - | - | - | €41,826 | €49,889 | €59,867 | €20,403 | €30,196 | ▲ 48.0% |
| Recurring financial income75 | €2,174 | €2,754 | €31,587 | €41,826 | €49,889 | €59,867 | €20,403 | €30,196 | ▲ 48.0% |
| Financial charges65/66B | - | - | - | €769 | €1,154 | €1,096 | €981 | €746 | ▼ 24.0% |
| Recurring financial charges65 | €972 | €881 | €785 | €769 | €1,154 | €1,096 | €981 | €746 | ▼ 24.0% |
| Profit (loss) for the period before taxes9903 | €13,862 | €13,978 | €43,047 | €52,586 | €59,474 | €61,793 | €34,498 | €49,763 | ▲ 44.2% |
| Income taxes67/77 | €3,616 | €3,644 | €6,402 | €7,224 | €7,325 | €6,373 | €6,077 | €8,452 | ▲ 39.1% |
| Profit (loss) for the period9904 | €10,246 | €10,334 | €36,645 | €45,362 | €52,149 | €55,419 | €28,420 | €41,311 | ▲ 45.4% |
| Profit (loss) for the period to be appropriated9905 | €8,826 | €8,840 | €36,645 | €45,362 | €52,149 | €55,419 | €28,420 | €41,311 | ▲ 45.4% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €1.1m | €1.1m | €1.2m | €1.0m | €1.0m | €1.1m | €1.1m | €1.2m | ▲ 4.7% |
| Fixed assets21/28 | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | ▲ 0.2% |
| Tangible fixed assets22/27 | €0.001m | €0.001m | €0.001m | €281 | €79 | €0 | - | €0.002m | - |
| Plant, machinery and equipment23 | - | - | - | €281 | €79 | €0 | - | €0.002m | - |
| Financial fixed assets28 | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | €0.9m | = |
| Current assets29/58 | €0.3m | €0.3m | €0.3m | €0.2m | €0.2m | €0.2m | €0.3m | €0.3m | ▲ 19.0% |
| Amounts receivable within one year40/41 | €0.04m | €0.004m | €0.02m | €0.01m | €0.02m | €0.05m | €0.05m | €0.03m | ▼ 40.9% |
| Trade receivables40 | - | - | - | €0.01m | €0.02m | €0.01m | €0.01m | €0 | ▼ 100% |
| Other amounts receivable41 | - | - | - | €12 | €0 | €0.04m | €0.04m | €0.03m | ▼ 25.3% |
| Current investments50/53 | €0.2m | €0.2m | €0.2m | €0.1m | €0.1m | €0.1m | €0.2m | €0.3m | ▲ 29.4% |
| Cash at bank and in hand54/58 | €0.03m | €0.06m | €0.06m | €0.07m | €0.07m | €0.07m | €0.009m | €0.02m | ▲ 127% |
| Deferred charges and accrued income490/1 | - | - | - | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | ▲ 1.2% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €1.1m | €1.1m | €1.2m | €1.0m | €1.0m | €1.1m | €1.1m | €1.2m | ▲ 4.7% |
| Equity10/15 | €0.6m | €0.6m | €0.4m | €0.4m | €0.5m | €0.5m | €0.5m | €0.6m | ▲ 7.8% |
| Contributions10/11 | €0.006m | €0.006m | - | €0.006m | €0.006m | €0.006m | €0.006m | €0.006m | = |
| Reserves13 | €0.3m | €0.3m | €0.1m | €0.1m | €0.2m | €0.2m | €0.2m | €0.3m | ▲ 18.4% |
| Non-distributable reserves130/1 | - | - | - | €0.002m | €0.002m | €0 | - | - | - |
| Reserves not available under the articles1311 | - | - | - | €0.002m | €0.002m | €0 | - | - | - |
| Tax-exempt reserves132 | - | - | - | €0.005m | €0.005m | €0.005m | €0.005m | €0.005m | = |
| Distributable reserves133 | - | - | - | €0.1m | €0.2m | €0.2m | €0.2m | €0.3m | ▲ 18.8% |
| Profit (loss) carried forward14 | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | €0.3m | = |
| Amounts payable17/49 | €0.6m | €0.6m | €0.8m | €0.6m | €0.6m | €0.6m | €0.6m | €0.6m | ▲ 1.9% |
| Amounts payable within one year42/48 | €0.6m | €0.6m | €0.8m | €0.6m | €0.6m | €0.6m | €0.6m | €0.6m | ▲ 1.9% |
| Trade debts44 | €0.002m | €0.001m | €0.003m | €0.002m | €0.003m | €0.004m | €0.005m | €0.02m | ▲ 232% |
| Suppliers440/4 | - | - | - | €0.002m | €0.003m | €0.004m | €0.005m | €0.02m | ▲ 232% |
| Taxes, remuneration and social security45 | - | - | - | €0.003m | €0.007m | €0.005m | €0.003m | €0.009m | ▲ 212% |
| Taxes450/3 | - | - | - | €0.001m | €0.005m | €0.002m | €0 | €0.006m | - |
| Remuneration and social security454/9 | - | - | - | €0.003m | €0.002m | €0.003m | €0.003m | €0.003m | ▲ 0.6% |
| Other amounts payable47/48 | - | - | - | €0.6m | €0.6m | €0.6m | €0.6m | €0.6m | ▼ 1.1% |
| Accrued charges and deferred income492/3 | - | - | - | - | - | - | €450 | €300 | ▼ 33.3% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €10,246 | €10,334 | €36,645 | €45,362 | €52,149 | €55,419 | €28,420 | €41,311 | ▲ 45.4% |
| + Depreciation and write-downs630 | €255 | €613 | €737 | €815 | €203 | €79 | €0 | €145 | - |
| Operating cash flow (approximation) | €10,501 | €10,947 | €37,381 | €46,178 | €52,352 | €55,498 | €28,420 | €41,455 | ▲ 45.9% |
| Investment in fixed assets (approximation) | - | -€1,074 | -€608 | €0 | €0 | €0 | €0 | -€2,087 | - |
| Change in cash | - | €28,674 | €2,855 | €8,530 | -€2,353 | €4,533 | -€64,799 | €11,822 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 13 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | abbreviated format | 29-06-2026 | 2026-00227876 |
| 31-12-2024 | abbreviated format | 30-06-2025 | 2025-00200816 |
| 31-12-2023 | abbreviated format | 05-07-2024 | 2024-00223427 |
| 31-12-2022 | abbreviated format | 05-07-2023 | 2023-00201669 |
| 31-12-2021 | abbreviated format | 30-07-2022 | 2022-20267455 |
| 31-12-2020 | abbreviated format | 28-07-2021 | 2021-42900018 |
| 31-12-2019 | abbreviated format | 03-07-2020 | 2020-26300463 |
| 31-12-2018 | abbreviated format | 08-07-2019 | 2019-30300506 |
| 31-12-2017 | abbreviated format | 24-07-2018 | 2018-36900063 |
| 31-12-2016 | abbreviated format | 20-07-2017 | 2017-33700467 |
Similar companies · same sector, comparable size
OptimizIT
BE 0839.415.234
Aalter · equity €569,113
INTERNATIONAL REAL ESTATE SERVICES
BE 0886.354.821
Ieper · equity €568,885
SR
BE 0538.600.220
Veurne · equity €569,522
BIPA
BE 0798.594.367
Zottegem · equity €569,616
MPX GROUP
BE 0692.818.144
Sint-Niklaas · equity €569,640
Of the 24,457 active companies whose main activity is activities of holding companies (NACE 64210), figures are known for 20,067. 13,651 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
1 director, last change in 2023
ANNAERT Inge
CurrentDirector (not named in the articles) · since 23-10-2023
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
1 of this company's 2 Belgian Official Gazette deeds has not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
1 person since 2023, 1 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| ANNAERT Inge |
|
Owners and capital
Capital and shareholders
Capital over the years
- 23-10-2023 Capital stated in the deed · 186 shares
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
-
99.78%
According to the 2025 annual accounts of JOIN PHARMA and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
1 current directorThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
29-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
30-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
05-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
31-12
Financial
Highest result from 2018 to 2025net €55,419 ▲6.3%
Net result €55,419, the highest in the series.
31-12
Financial
Equity above €500,000equity €508,241 ▲10.1%
A profit in every financial year since 2018 builds equity to €508,241.
23-10
Gazette deed
Resignation: ANNAERT Inge (director)Appointment: ANNAERT Inge (director) · Registered office clause · Power of attorney11 facts ▸
Gazette deed
Resignation: ANNAERT Inge (director)
Appointment: ANNAERT Inge (director) · Registered office clause · Power of attorney11 facts ▸
- Registered office clause, “Lindenberg 16,3080 Tervuren” (deed in Dutch)
- Power of attorney, Mostaert,Maere & Van Elslande
- Power of attorney
- General meeting, 18-10-2023
- Amendment of the articles (2 times)
- Capital conversion, EUR, “van rechtswege omgezet” (deed in Dutch)
- Other provision, “beschikbaar voor uitkering” (deed in Dutch)
- Director resignation, ANNAERT Inge (director)
- Director appointment, ANNAERT Inge (director (not named in the articles))
- Other provision, “uitoefening mandaat als zaakvoerder, kwijting ontslagnemende bestuurder” (deed in Dutch)
- Capital
05-07
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
30-07
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
28-07
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
03-07
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format
2019
08-07
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2018
24-07
NBB filing
Annual accounts filed
financial year 2017 · abbreviated format
2017
20-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
1 of 2 deeds read
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Register details
Identification
Legal formPrivate limited company
Founded18-06-2012
Financial year end31-12
Activities, NACEBEL 2025
64210Activities of holding companies
68110Buying and selling of own real estate
68201Renting and operating of own or leased residential real estate, excluding social housing
70200Business and other management consultancy
E-invoicing
Reachable via Peppol
Peppol ID
0208:0846679346
Also
9925:BE0846679346
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 28 October 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.
Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.
Sites & property
Location & real-estate footprint
Registered office, Tervuren · 1 establishment unit since 2012
Ground area
1,901 m²
Building footprint
215 m²
Building volume
975 m³
Parcel 24114B0445/00S002, Flanders · tallest building 6.6 m. Linked by address, not a title deed.
2
companies at this address
See who is registered here
1 establishment unit
Join Pharma
since 2012unit no. 2.210.535.671
1 parcel
Flanders
1
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 24114B0445/00S002 | Flanders | 1,901 m² | 1 · 215 m² | 6.6 m · 2 |
How the parcels are linked
Good to know
The parcel matches the address exactly.
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- JOIN PHARMA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Enkel besluit bestuursorgaan, Vlaams Gewest” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- “Één of meer bestuurders, met of zonder beperking van duur” (deed in Dutch)“Vaste of evenredige vergoeding, algemene kosten,los van representatie-,reis- en verplaatsingskosten” (deed in Dutch)
Capital, shares and profit
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- “Procedure- en expertisekosten voor helft overdrager en helft koper(s) naar evenredigheid aantal bij meerdere kopers;zelfde bij weigering…” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Last Friday of June at 20:00
Oversight and winding up
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Vormen vereist voor statutenwijziging, elk moment” (deed in Dutch)
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Een of meerdere vereffenaars aanduiden,bevoegdheden omlijnen,vergoeding bepalen, bestuurder(s) in functie als vereffenaar(s) krachtens…” (deed in Dutch)